Welcome to our dedicated page for Springworks Therapeutics news (Ticker: SWTX), a resource for investors and traders seeking the latest updates and insights on Springworks Therapeutics stock.
SpringWorks Therapeutics reports developments in rare-disease and oncology medicines as a healthcare company of Merck KGaA, Darmstadt, Germany. Its news centers on OGSIVEO® (nirogacestat), an oral gamma secretase inhibitor for adults with progressing desmoid tumors who require systemic treatment, and EZMEKLY® (mirdametinib) for symptomatic, inoperable NF1-associated plexiform neurofibromas.
Recurring updates include clinical data publications from the Phase 3 DeFi trial, U.S. and European regulatory actions, orphan-drug designations, product commercialization, and targeted-therapy pipeline work in solid tumors and hematological cancers. Corporate news also reflects SpringWorks' completed acquisition by Merck KGaA and related public-company status changes.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
On April 17, 2023, SpringWorks Therapeutics and BeiGene presented updated clinical data from a Phase 1b trial focused on the RAF dimer inhibitor, lifirafenib, in combination with the MEK inhibitor, mirdametinib. This trial targets patients with advanced solid tumors driven by genetic mutations in RAS and RAF pathways. The oral presentation at the AACR Annual Meeting highlighted promising early results, indicating a favorable safety profile with low instances of severe adverse events. Among 62 efficacy-evaluable participants, 23% experienced confirmed objective responses, with notable success in specific cancer types, including a 59% response rate in low-grade serous ovarian cancer. The trial is advancing into a dose-expansion phase targeting biomarker-selected patients in late 2023.